AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06154148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sustained Diagonal Flexion positioning
Description: This position is a semi reclined positioning, the infant is off-center and semi-reclined on the mother's chest its body-axis is slightly flexed, with the limbs retracted in a preventive posture and the head in line with the body axis, moderately externally rotated hips in flexion-abduction, with adducted shoulders. The infant's head turns toward the mother's face and is located between the nipple and the clavicule. Their arms and legs are flexed,in a naturally adopted asymmetrical tonic neck posture, according to the infant's term and comfort. The infant is naked and positioned inside the mother's clothes.
Study NCT06418568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra-pulsed Shockwave Therapy Device by Shenzhen Lifotronic Technology Co., Ltd.
Description: The intervention involves treating melasma using tranexamic acid (aminomethylbenzoic acid) delivered through ultra-pulsed shockwave therapy on one side of the face, while the other side receives topical application of tranexamic acid at the same concentration. The shockwave therapy parameters are tailored based on patient tolerance. Each patient undergoes 3 treatment sessions spaced 3 weeks apart, followed by a 4-week follow-up period. Facial skin is assessed using the VISIA system before each treatment and at the 4-week follow-up, evaluating the Melasma Area Severity Index (MASI). Patient and researcher satisfaction levels are rated on a scale of 1 to 5. Adverse reactions, including short-term effects like pain and swelling, and potential long-term effects such as allergic reactions and hyperpigmentation, are monitored after each treatment session.
Study NCT05163834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod
Description: intravenous infusion of efgartigimod
Study NCT05163834 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion of placebo
Study NCT05163834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX 23
Description: PNEUMOVAX 23 vaccine
Study NCT05163834 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PNEUMOVAX 23
Description: PNEUMOVAX 23 vaccine
Study NCT06207071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA
Description: DHA supplementation
Study NCT04905823 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: assessment of humoral, immune cell response and glycemia
Study NCT03177746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine/Tadalafil 30/20 mg film coated tablet
Description: During 4-weeks treatment period, patients will take one Dapoxetine/Tadalafil 30/20 mg film coated tablet 1-3 hours before sexual intercourse.~Study drug should not be used more than 1 tablet every 24 hours during the treatment.
Study NCT06154148 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional prone position
Description: The infant is placed vertically between the mother's breasts firmly attached to the chest and below their clothes.
Study NCT05582512 — intervention group
Intervention type: OTHER
Intervention: sequelae tracking
Description: An integrated outpatient clinic for Long COVID-19 Syndrome in Children will be established to conduct systematic tracking of body, lung function, nerves and psychology. Children with neurological complications or other confirmed diagnoses will undergo physical, neurological, pulmonary function and brain MRI and neurophysiological examinations, sleep examinations, and conduct psychiatric clinical diagnostic interviews to establish a psychiatric diagnosis. Status and family social function, the intelligence development status was examined by intelligence test, and cognitive function was measured by neuropsychological test. Understand the microbial flora, immune function and incidence of allergic diseases after long-term COVID-19 infection
Study NCT05373758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care treatment strategy
Description: Management of virologic failure on TLD using the Standard of Care strategy
Study NCT05373758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Care treatment strategy
Description: Management of virologic failure on TLD using the Individualized Care strategy
Study NCT05373758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate Switch
Description: Management of virologic failure on TLD using the Immediate Switch strategy
Study NCT01006096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 100mg tablet, once daily for 16 weeks
Study NCT01006096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: placebo tablet (lactose), once daily for 16 weeks
Study NCT05599412 — intervention group
Intervention type: DRUG
Intervention: Lorviqua
Description: As provided in real world practice
Study NCT05247125 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Blue light exposure + Melatonin treatment
Description: 3 mg Melatonin pill will be given 1 hour before going to bed. Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.
Study NCT05247125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Description: 3 mg Melatonin pill will be given 1 hour before going to bed.
Study NCT05247125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue light exposure
Description: Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.
Study NCT05247125 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo light exposure will be performed by using lamp turned off; and placebo pill will be given in the evening
Study NCT05506072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction therapy
Description: Blood Flow Restriction involves the application of a tourniquet to an extremity to partially restrict the arterial and venous blood flow to stimulate localized cellular and systemic hormonal changes that occur in high intensity exercise. BFR Training may produce similar cellular and muscular responses to cause hypertrophy when exercise is performed at low intensity. Studies have compared BFR therapy in the lower extremities with light load resistance exercise to light load resistance alone and observed greater improvements in the BFR group. A recent systematic review further identified that adding BFR to exercise effectively augments muscle strength and size. Additionally, BFR has been shown to be applied in a safe manner with low risk for complications. With this growing body of evidence supporting BFR, it is becoming increasingly common in rehabilitation
Study NCT05678933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine (75mg/ m2) will be administered at day 1-5 by subcutaneous injection of each 21-day cycle.
Study NCT05678933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide (20 mg) will be taken orally twice a week for two weeks of each 21-day cycle.
Study NCT05506072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood flow restriction therapy
Description: Blood Flow Restriction involves the application of a tourniquet to an extremity to partially restrict the arterial and venous blood flow to stimulate localized cellular and systemic hormonal changes that occur in high intensity exercise. BFR Training may produce similar cellular and muscular responses to cause hypertrophy when exercise is performed at low intensity. Studies have compared BFR therapy in the lower extremities with light load resistance exercise to light load resistance alone and observed greater improvements in the BFR group. A recent systematic review further identified that adding BFR to exercise effectively augments muscle strength and size. Additionally, BFR has been shown to be applied in a safe manner with low risk for complications. With this growing body of evidence supporting BFR, it is becoming increasingly common in rehabilitation
Study NCT05506072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physical Thearapy
Description: Participants will be randomized into their assigned group of receiving standard therapy without BFR by a blinded therapist within the study using a computer generated randomization formula Participants will then visit the clinic for study testing at six weeks, 12 weeks, and six months after their surgery. During each of these visits, they will be asked to complete a survey, and then their shoulder strength and flexibility will be measured. Each study visit will last approximately 30 minutes. Participants will also attend 12-18 shoulder rehabilitation sessions in the clinic over six weeks from the six week to 12 week mark (about two to three sessions per week). Each rehabilitation session will last approximately 30 minutes and consist of standard rehabilitation exercises without BFR.~Between the 12-week follow-up and 6-month follow-up, participants will receive standard post-surgical rehabilitation for their specific shoulder surgery without Blood Flow Restriction training.
Study NCT06353152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection
Description: single-/multiple-dose infusion
Study NCT05678933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
Study NCT05678933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
Study NCT05678933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
Study NCT05678933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
Study NCT05415254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Calcitriol supplementation orally
Study NCT04531956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic decision aid s-decided
Description: The intervention will consist of implementing a patient decision aid (PtDA) in general practice. The patient decision aid will be developed in line with the systematic development process specified by the International Patient Decision Aids Standards (IPDAS)
Study NCT05437952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taurine and Exercise (Tau+Ex)
Description: Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks
Study NCT05437952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo and Exercise (PL+Ex)
Description: Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks.
Study NCT05437952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taurine (Tau)
Description: Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
Study NCT05437952 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PL)
Description: Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
Study NCT05255835 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Semiconductor Knee Sleeves
Description: semiconductor elements germanium and carbon within the cotton fabric
Study NCT05255835 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cotton Knee Sleeves (Placebo)
Description: cotton fabric knee sleeves
Study NCT04952428 — intervention group
Intervention type: BEHAVIORAL
Intervention: Re-examination visit (today visit)
Description: Re-examination visit (today visit) A guidebook will be prepared to standardize procedures throughout the protocol, step by step, for all questionnaires and evidence collection. The data will be transferred to a computerized database.~The clinician will review with the patient the Information and Medication History Forms and record the anthropometric, socio-demographic and clinical information. Candidates will undergo an oral pathology examination and a full-mouth manual probing using a periodontal probe SONDA PA_ON (Orange Dental®, Aspachstr, Biberach, Germany) to determine their periodontal and peri-implant status. Clinical and radiographic examination will be performed. Moreover, signs as presence of suppuration, bleeding, redness, probing depth must be recorded at 6 sites per implant applying. As well, a specific survey about tobacco habits including modification of Fagestrom \& Richmond test will be conducted.
Study NCT05754411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]STI-1558
Description: Fasting oral administration of 600 mg \[ 14C \] STI-1558 ( about 100 μCi ) solution.
Study NCT05965245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suubi-Mhealth
Description: Suubi-Mhealth is a theoretically-based digital therapeutics tool that aims to provide educational content on depression while considering the unique needs of SSA youth living with HIV. This educational content will be aligned with scientific recommendations for cognitive-behavioral therapy for adherence and depression as applied to HIV medication adherence. Core instruction will include psychoeducation on the interplay between HIV and depression; minimizing cognitive distortions related to ART adherence and stigma, as well as depression; challenging negative automatic thoughts; analysis and development of behavioral skills; reducing environmental stressors. Suubi-Mhealth will also have a social networking center in which patients can contact the research team, peers who are also taking part in this intervention, and other trusted individuals such as loved ones. Other features include tools for setting and monitoring goals, and a clinical management dashboard for the research team.
Study NCT05965245 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Suubi-Mhealth
Description: Suubi-Mhealth is a theoretically-based digital therapeutics tool that aims to provide educational content on depression while considering the unique needs of SSA youth living with HIV. This educational content will be aligned with scientific recommendations for cognitive-behavioral therapy for adherence and depression as applied to HIV medication adherence. Core instruction will include psychoeducation on the interplay between HIV and depression; minimizing cognitive distortions related to ART adherence and stigma, as well as depression; challenging negative automatic thoughts; analysis and development of behavioral skills; reducing environmental stressors. Suubi-Mhealth will also have a social networking center in which patients can contact the research team, peers who are also taking part in this intervention, and other trusted individuals such as loved ones. Other features include tools for setting and monitoring goals, and a clinical management dashboard for the research team.
Study NCT05271734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lid retractor placement
Description: Insertion of a lid retractor to find out if the corneal limbus is exposed in 360 degress
Study NCT05310916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab plus another oral hypoglycemic agent
Description: Dapagliflozin is a member of Sodium-glucose co-transporter 2 inhibitors class which in addition to its glucose control effect, has reno-protective and cardioprotective effects, controls blood pressure and causes weight loss.
Study NCT05310916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two oral hypoglycemic agents other than dapagliflozin
Description: Two oral anti-diabetic agents not including sodium-glucose co-transporter 2 inhibitors
Study NCT06028672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 200mg q2w intravenous
Study NCT06028672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actinomycin-D
Description: 1.25mg/m2，2mg max dose, q2w, intravenous
Study NCT06028672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actinomycin-D
Description: 1.25mg/m2，2mg max dose, q2w, intravenous
Study NCT06052189 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound
Description: Ultrasonographic parameters: in the parasagittal plane (1cm from midline) with the patient lying supine, without a pillow, head, and neck in the neutral position, looking straight ahead with mouth closed and the tongue on the floor of the mouth without any movement.
Study NCT04742972 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: SABR is delivered to all sites of oligometastasis with continuation of Enzalutamide. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in SOC Arm.
Study NCT04742972 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SOC
Description: Three options:~1. Continuation of Enzalutamide~2. Observation~3. Switch to next line treatment
Study NCT05395039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VCHIPS
Description: Participants in this group will have the opportunity to receive virtual visits with the patient during the hospital stay, led by a study nurse.
Study NCT06266936 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: The study involves longitudinal monitoring of the state of health of the specific population of students in care courses, from their entry into university studies (first year) until their final year of study, i.e. from 5 to 13 years depending on the course and the different universities.
Study NCT06283225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pia-App
Description: The dysmenorrhoea app (Pia-App) is evidence-based and helps patients to implement continuous multimodal (pain) treatment that is integrated into everyday life. Symptoms, events, influencing factors and examinations can be recorded in a specialised diary. Diary evaluations and learning modules on dysmenorrhoea and other relevant topics promote understanding of the condition and self-efficacy. An intelligent evaluation suggests suitable evidence-based and appropriate exercises. In the learning modules, patients can learn about the menstrual cycle, menstrual pain and self-management methods in a structured way. For example, there are structured courses on physiotherapy, yoga, stress reduction and relaxation methods such as progressive muscle relaxation and autogenic training.
Study NCT05343715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agalsidase beta from Biosidus 1 mg/kg
Description: Patients received an infusion of 1 mg/kg of Agalsidase Beta from Biosidus. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
Study NCT05678933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.
Study NCT05678933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.
Study NCT05678933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.
Study NCT05678933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.
Study NCT05048199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pressure regulated volume-controlled mode of ventilation
Description: Cardiac output non-invasive monitor for measuring SV. Hemodynamic variables including heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP), stroke volume (SV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), and systolic time ratio (STR), Arterial oxygen saturation (Sao2), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be recorded.~These variables will be obtained before induction of anaesthesia (T1) skin incision (T2), then every 30 min till the resection of the urinary bladder (T3a, T3b, T3c, .... etc). The mode of ventilation will swift to the other mode 5 minutes after cystectomy (T4), then every 30 min till end of the urinary diversion (T5a, T5b, T5c, .... etc), end of surgery (T6), and postoperative every 4h for 24 hours( P1-P6).